- About us
- Clinical trials
- News & Publications
PPF Group is one of the largest investment groups in Central and Eastern Europe. PPF invests in multiple market segments including financial services, telecommunications, biotechnology, real estate and mechanical engineering. PPF Group’s growth rests on the development of traditional and new industries, the building of modern infrastructure, the digital economy and linking up local talents and capabilities with global opportunities. PPF Group’s reach spans from Europe to North America and across Asia. The Group owns assets worth almost EUR 49 billion (as at 31 December 2019) and employs 135,000 people globally. For more information visit PPF Group.
SOTIO is leading the biotechnology efforts of PPF Group by building a diverse portfolio through its in-house research and development, collaborations with external partners, in-licensing deals, investments and acquisitions.
As part of the PPF Group, SOTIO closely cooperates with its partners to drive preclinical and clinical development for projects added to the SOTIO pipeline. The aim is to rapidly advance these projects to clinical trials and towards commercialization. To date, SOTIO has established partnerships with Cytune Pharma (France) regarding the interleukin-15 (IL-15) superagonist program and NBE-Therapeutics (Switzerland) regarding a new Antibody-Drug Conjugate program. In addition to SOTIO, PPF also invested in Cytune Pharma, NBE-Therapeutics, Cellestia Biotech (Switzerland) and Autolus Therapeutics (UK).